Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 1
2015 1
2016 3
2017 2
2018 4
2019 7
2020 13
2021 9
2022 10
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy.
Martin MV, Aguilar-Rosas S, Franke K, Pieterse M, van Langelaar J, Schreurs RR, Bijlsma MF, Besselink MG, Koster J, Timens W, Khasraw M, Ashley DM, Keir ST, Ottensmeier CH, King EV, Verheij J, Waasdorp C, Valk PJM, Engels SA, Oostenbach E, van Dinter JT, Hofman DA, Mok JY, van Esch WJE, Wilmink H, Monkhorst K, Verheul HMW, Poel D, Hiltermann TJN, van Kempen LC, Groen HJ, Aerts JGJV, van Heesch S, Lowenberg B, Plasterk R, Kloosterman WP. Martin MV, et al. Among authors: hiltermann tjn. Cancer Immunol Res. 2024 Apr 4. doi: 10.1158/2326-6066.CIR-23-0158. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38573707
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.
Zwierenga F, van Veggel BAMH, van den Berg A, Groen HJM, Zhang L, Groves MR, Kok K, Smit EF, Hiltermann TJN, de Langen AJ, van der Wekken AJ. Zwierenga F, et al. Among authors: hiltermann tjn. Cancer Treat Rev. 2023 Nov;120:102628. doi: 10.1016/j.ctrv.2023.102628. Epub 2023 Sep 19. Cancer Treat Rev. 2023. PMID: 37797348 Free article. Review.
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV, Janning M, Rifaela N, Azpurua MLA, Kropidlowski J, Loges S, Lozano N, Sartori A, Irwin D, Lamy PJ, Hiltermann TJN, Groen HJM, Pantel K, Kempen LCV, Wikman H, Schuuring E. Leest PV, et al. Among authors: hiltermann tjn. Int J Mol Sci. 2023 Aug 29;24(17):13390. doi: 10.3390/ijms241713390. Int J Mol Sci. 2023. PMID: 37686200 Free PMC article.
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer.
Muller M, Best MG, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG, Nogarede T, Visser L, Schouten RD, van den Broek D, Hummelink K, Monkhorst K, de Langen AJ, Schuuring E, Smit EF, Groen HJM, Wurdinger T, van den Heuvel MM. Muller M, et al. Among authors: hiltermann tjn. Tumour Biol. 2024;46(s1):S327-S340. doi: 10.3233/TUB-220037. Tumour Biol. 2024. PMID: 37270827 Free article.
The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.
Hiddinga BI, Slebos DJ, David Koster T, Hijmering-Kappelle LBM, Hiltermann TJN, Kievit H, van der Wekken AJ, de Jonge G, Vliegenthart R, Van De Wauwer C, Timens W, Bensch F. Hiddinga BI, et al. Among authors: hiltermann tjn. Lung Cancer. 2023 Mar;177:37-43. doi: 10.1016/j.lungcan.2023.01.012. Epub 2023 Jan 24. Lung Cancer. 2023. PMID: 36708592 Free article.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: hiltermann tjn. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuuring E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ. Gijtenbeek RGP, et al. Among authors: hiltermann tjn. ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267895 Free PMC article.
Detection and localization of early- and late-stage cancers using platelet RNA.
In 't Veld SGJG, Arkani M, Post E, Antunes-Ferreira M, D'Ambrosi S, Vessies DCL, Vermunt L, Vancura A, Muller M, Niemeijer AN, Tannous J, Meijer LL, Le Large TYS, Mantini G, Wondergem NE, Heinhuis KM, van Wilpe S, Smits AJ, Drees EEE, Roos E, Leurs CE, Tjon Kon Fat LA, van der Lelij EJ, Dwarshuis G, Kamphuis MJ, Visser LE, Harting R, Gregory A, Schweiger MW, Wedekind LE, Ramaker J, Zwaan K, Verschueren H, Bahce I, de Langen AJ, Smit EF, van den Heuvel MM, Hartemink KJ, Kuijpers MJE, Oude Egbrink MGA, Griffioen AW, Rossel R, Hiltermann TJN, Lee-Lewandrowski E, Lewandrowski KB, De Witt Hamer PC, Kouwenhoven M, Reijneveld JC, Leenders WPJ, Hoeben A, Verdonck-de Leeuw IM, Leemans CR, Baatenburg de Jong RJ, Terhaard CHJ, Takes RP, Langendijk JA, de Jager SC, Kraaijeveld AO, Pasterkamp G, Smits M, Schalken JA, Łapińska-Szumczyk S, Łojkowska A, Żaczek AJ, Lokhorst H, van de Donk NWCJ, Nijhof I, Prins HJ, Zijlstra JM, Idema S, Baayen JC, Teunissen CE, Killestein J, Besselink MG, Brammen L, Bachleitner-Hofmann T, Mateen F, Plukker JTM, Heger M, de Mast Q, Lisman T, Pegtel DM, Bogaard HJ, Jassem J, Supernat A, Mehra N, Gerritsen W, de Kroon CD, Lok CAR, Piek JMJ, Steeghs N, van Houdt… See abstract for full author list ➔ In 't Veld SGJG, et al. Among authors: hiltermann tjn. Cancer Cell. 2022 Sep 12;40(9):999-1009.e6. doi: 10.1016/j.ccell.2022.08.006. Epub 2022 Sep 1. Cancer Cell. 2022. PMID: 36055228 Free article.
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: hiltermann tjn. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
51 results